SAN MATEO, Calif., June 10 /PRNewswire/ -- When asked which company stood out at last week's ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail, Inc., a leader in oncology primary market research and influence network mapping solutions to the Global Life Sciences Industry.
In a brief on-line survey of 103 oncologists conducted soon after the
close of the conference, AlphaDetail was able to gather some interesting
feedback about oncologist perceptions of the meeting. The ASCO Annual
Meeting attracts more than 30,000 attendees and is considered the premier
educational and scientific event in the oncology community.
-- 60% of US oncologists attended the ASCO Annual Meeting.
-- Oncologists rate Genentech #1 on overall image in oncology and cite it
as the top company that stood out above the others at ASCO.
-- Oncologists cite the following as the three most important pieces of
data presented at ASCO:
-- KRAS status predicts response to first-line cetuximab for
metastatic colorectal cancer.
-- Erbitux (cetuximab) + platinum-based chemotherapy extends overall
survival in NSCLC vs. chemotherapy alone.
-- Zometa (zoledronic acid) increases survival for premenopausal
patients who received adjuvant endocrine therapy for early breast
To learn more about this study, please contact Bob Latshaw at Bob.Latshaw@alphadetail.com or (215) 259-5601.
About AlphaDetail, Inc.:
At AlphaDetail, we have an unparalleled commitment to our clients. We
are a full-service primary market research firm, with a particular emphasis
in large and complex quantitative studies for the global healthcare
community. AlphaDetail is built on one of the industry's strongest
foundations that includes a large team of exceptional analytical
specialists, the industry's leading techno
|SOURCE AlphaDetail, Inc.|
Copyright©2008 PR Newswire.
All rights reserved